Creative Biolabs is a world-leading service provider of application-specific antibody development. Here, we introduce our in vitro diagnostic (IVD) antibody development and immunoassay development services targeting the C-reactive protein (CRP) marker. We are confident that our commitment to science and research will enable us to offer you the best products and services.
Introduction of C-reactive Protein Marker
C-reactive protein (CRP), named for its capacity to precipitate the somatic C-polysaccharide of Streptococcus pneumoniae, is a member of the pentraxin family of calcium-dependent ligand-binding plasma proteins. The molecule of CRP is composed of five identical nonglycosylated polypeptide subunits, each containing 206 amino acid residues. As one of the major acute-phase proteins, CRP provides the first line of defense of pathogen and its level can increase from ∼1 μg/ml to as much as 1000-fold within 48 h after the onset of inflammation or tissue injury. In addition, CRP shares similar functional properties with the Igs, such as, the ability to promote agglutination, complement fixation, bacterial capsular swelling, phagocytosis and precipitation of polycationic and polyanionic compounds. Moreover, CRP has a role in the clearance of bacteria and of dying and altered cells and might also have more complex immunomodulatory functions.
Fig.1 Functional CRP pathways (Rhodes.2011)
C-reactive Protein Marker of Liver Cirrhosis
In the past years, numerous studies have suggested that the level of CRP in serum can be used as a sensitive marker of inflammation. It has been reported that plasma CRP concentration is significantly increased in various conditions such as bacterial infection, abscess, Chrohn's disease, connective tissue disorders, neoplasia, trauma and necrosis. What's more, the excellent correlation of circulating CRP concentrations with the severity, extent and progression of many different pathologies and the prognostic significance of these associations are consistent with CRP not just being a marker of disease but also contributing to pathogenesis. Most importantly, CRP has recently been identified as a potential prognostic marker in cirrhotic patients for the level of CRP is higher than that of healthy people.
C-reactive Protein Marker of Sepsis
Because of the non-specific nature of the acute-phase response and the resulting rise in CRP levels, CRP cannot be used alone to diagnose any condition. CRP can, however, provide supportive evidence for the diagnosis of several infections, such as sepsis. For instance, when certain criteria are present, such as high fever and increased respiratory rate, CRP values can be used to diagnose an inflammatory condition or infection, which could develop into sepsis. CRP in combination with a procalcitonin (PCT) test can effectively distinguish sepsis from systemic inflammation. Sepsis is the result of an uncontrolled immune-response infection and has a mortality rate close to 30 %. CRP is a well-established biomarker of infection, inflammation, and sepsis and is widely used in clinics and emergency departments. The usefulness of CRP measurements in the diagnosis of sepsis has been studied previously in several clinical settings, and various studies have suggested that the CRP cut-off level for infection diagnosis.
CRP Marker of Myocardial Infarction
MI is one kind of cardiovascular diseases which occurs when the artery of the heart is blocked. It has been reported that atherosclerosis is a chronic inflammatory disease and CRP plays an important role in the pathological process of atherosclerosis formation. CRP is able to bind to the receptors of macrophages and monocyte receptors and induce the synthesis and secretion of many proinflammatory signaling molecules. It has been studied that the CRP level always increases in most patients with MI.
Recently, studies have demonstrated that the increased high sensitivity CRP (hsCRP) level in most patients with AMI reveals involvement of inflammation in the etiopathogenesis of MI and has prognostic effects in AMI. Besides, it has also indicated that serum hsCRP levels are strong predictors of prognoses in patients with AMI. Raised levels of hsCRP at the time of admission suggest a poor prognosis in patients with AMI. Therefore, hsCRP is a potential marker for the diagnosis and prognosis prediction of MI. In this case, CRP has been a potential marker for the diagnosis and prognosis prediction of MI.
IVD Antibody Development Services for CRP Marker
Antibodies are core elements for antibody-based immunoassays for detecting and quantifying antigens of interest in different samples such as the serum, urine, tissue preparations, and so on. At Creative Biolabs, we offer a full range of antibody development, antigen & antibody conjugation, and IVD kit development services to clients across the globe. We develop IVD antibodies that can be applied for different immunoassay formats, including ELISAs, lateral flow immunochromatographic assays, western blot, and flow cytometry.
Creative Biolabs has extensive experience and mature technology platforms in generating and developing IVD antibodies. For more details and information, please feel free to contact us and get a quote.
References
For Research Use Only.
